607371-03-9

Basic information

• Product Name: 5-bromo-N4-ethylpyridine-3,4-diamine
• Synonyms: 5-bromo-N4-ethylpyridine-3,4-diamine;3,4-PYRIDINEDIAMINE, 5-BROMO-N4-ETHYL;5-bromo-N4-ethyl-3,4-Pyridinediamine
• CAS NO: 607371-03-9
• Molecular Formula: C7H10BrN3
• Molecular Weight: 216.08
• Mol File: 607371-03-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.576
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 5-bromo-N4-ethylpyridine-3,4-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-N4-ethylpyridine-3,4-diamine(607371-03-9)
• EPA Substance Registry System: 5-bromo-N4-ethylpyridine-3,4-diamine(607371-03-9)

Safety Data

• Hazardous Substances Data: 607371-03-9(Hazardous Substances Data)

Usage

General Description

5-Bromo-N4-ethylpyridine-3,4-diamine is a chemical compound that is commonly used in pharmaceutical research and development. It is a derivative of pyridine-3,4-diamine and contains a bromine atom and an ethyl group attached to the nitrogen atom at position 4. 5-bromo-N4-ethylpyridine-3,4-diamine is known for its potential biological activities, including its role as an inhibitor of certain enzymes and receptors. It has been studied for its potential use in the treatment of cancer and other diseases. Additionally, 5-Bromo-N4-ethylpyridine-3,4-diamine is used in the synthesis of various organic molecules and is a valuable building block in medicinal chemistry.

Upstream product

• 562825-95-0 ethyl-(3-nitropyridin-4-yl)amine 
• 607371-01-7 ethyl-(3-bromo-5-nitropyridin-4-yl)amine 

Downstream Products

• 607370-99-0 4-(7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)oxadiazolidin-3-ylamine 
• 842143-97-9 (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile 

Relevant articles and documents

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3- piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3β. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3β phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.

INHIBITORS OF Akt ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yI compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.